Company Focus
Regeneron Pharmaceuticals Inc
Latest Regeneron Pharmaceuticals Inc News
Biotechnology
The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents. 17 October 2024
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
Latest News & Features of interest to Regeneron Pharmaceuticals Inc
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
US biotech major Gilead Sciences was trading nearly 2% higher in pre-market on Thursday after announcing its third-quarter 2024 financial results and latest guidance for 2024 as a whole. 7 November 2024
Biotechnology
Oncology-focused biotech company Tango Therapeutics announced an update on its PRMT5 program. Tango noted that, based on positive data from the dose escalation and early dose expansion cohorts of the TNG462 Phase I/II clinical trial, it has selected TNG462 to move forward into full development. 7 November 2024
Biotechnology
Maryland-based MacroGenics, a biopharma focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, has provided an update on its lead antibody-drug conjugate (ADC) vobramitamab duocarmazine (vobra duo). 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
US drugmaker Sarepta Therapeutic saw its shares gain 2.4% to $127.97 as it reported financial results for the third quarter 2024. 7 November 2024
Pharmaceutical
PrognomiQ has announced a series D financing round of $34 million, led by Seer, bringing the firm’s total funding to over $135 million since its founding in September 2020. 6 November 2024
Pharmaceutical
USA-based Acadia Pharmaceuticals has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction. 6 November 2024
Pharmaceutical
The market for ROS1 inhibitors, targeted treatments primarily used in non-small cell lung cancer (NSCLC), is set to see significant growth as novel therapies gain traction and a precision medicine approach reshapes the oncology landscape. 6 November 2024
Biotechnology
GSK’s Arexvy (RSV vaccine) has received an expanded approval in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50-59 who are at increased risk. 6 November 2024
Latest In Brief for Regeneron Pharmaceuticals Inc
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Latest Relevant Ones To Watch News
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
13 November 2024
12 November 2024
8 November 2024
5 November 2024
30 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze